“a decreasing trend”

However, trends in certifying death as “old age” showed a decreasing trend over 10 years, notably in hospital (−0.87% annually, 95% CI −1.09 to −0.65%, p <0.001) with increasing use of dementia (0.34% annually, 95% CI 0.14%–0.54%, p = 0.004).

Meanwhile, the DDDs of original trastuzumab (Herceptin) had a decreasing trend ( P < 0.001, Figure 5E ).

In RG and IS, we furthermore observed a decreasing trend of aerobes and facultative anaerobes ( p < 0.001 and p = 0.002, respectively) and an increase of anaerobes during the observational period ( p < 0.001 for both, Figure 6 ).

Among the different BALAD-2 scores, we found that the 5-year survival rate showed a decreasing trend with each increase from ≤2 to 4 (68.1%, 60.8% and 34.5%; Log-rank P <0.001; Figure 1 B).

The variables “family history of cancer” (p<0.001), “alcoholism” (p<0.001), “smoking” (p<0.001), “TNM staging” (p<0.001) had a decreasing trend, while “clinical start of treatment” (p<0.001), “origin” (p=0.008) and “occupation” (p<0.001) indicated an increasing trend.

Alanine transaminase levels presented a decreasing trend ( p < 0.001), whereas creatinine levels remained unchanged ( p > 0.05), with consistent trends across PH subgroups.

Total dissolved solids and absorbance measurements exhibited a decreasing trend with increasing concentration (effect size = 0.87, p < 0.001 ), supporting an inhibitory effect under the tested conditions.

Nevertheless, a decreasing trend (p < 0.001) was observed for history of acute otitis media (AOM-history) and AB-use in the 3 months before sampling.

Combination therapy was the predominant pattern of treatment, monotherapy showed a decreasing trend over time ( p < 0.001), while the proportion of dual combination therapy and triple or more combination therapy kept on increasing during the 5-year period (both p < 0.001).

After de-escalation training, the average duration of physical restraint of experimental group presented a decreasing trend ( F time = 9.174, P < 0.001) and was remarkably lower than control group ( F group = 5.054, P = 0.048) ( Figure 4 ).

For lung cancer, there was evidence of a decreasing trend (P<0.001 for overall trend and P=0.14 for trend after separate adjustment for ever angiotensin receptor blocker use—that is, ignoring the zero use category).

It was observed that there was a significant increasing trend in RSA rates and a decreasing trend in HA and TSA rates over time (p < 0.001).

Time effects on weight (wk 4: hazard ratio [HR]=0.058, wk 8: HR=0.011; P <.001) and BMI (wk 4: HR=0.668, wk 8: HR=0.296; P <.001) were significant, indicating a decreasing trend over time that was statistically significant ( P <.001).

The seasonal Mann–Kendall trend test showed a significant decreasing trend in malaria cases over the study period (z = − 6.04, p < 0.001) as well as a decreasing trend in mean temperature (z = − 12.06, p < 0.001).

In contrast, anti-HAV IgM titers exhibited a decreasing trend with age ( p < 0.001; Figure 7 D). 4.

reported that throughout the entire study period, the bexarotene group exhibited increased cholesterol levels, whereas the placebo group showed a decreasing trend (F 2,317 = 33.7, p < 0.001).

Results Chronic hepatitis B showed a decreasing trend (Exp[B] = 0.975, P < 0.001), whereas alcohol showed an increasing trend (Exp[B] = 1.013, P = 0.003), occupying the most common etiology in 2017.

The percentage of the female participants increased significantly in higher quartiles of the DGAI score (29.2% vs 25.9%; p=0.04) while having a decreasing trend in males (17.4% vs 30.3%; p<0.001).

All‐cause 30‐day mortality due to BM The overall 30‐day mortality of BM was 9% (981/10,771); it was 3% in children and 14% in adults, with a decreasing trend since 1987 in adults, particularly among the elderly (annual change −2%, CI95% −4 to −1, p < 0.001), but also among nonvaccinated adults (annual change −3%, CI95% −5 to −2, p < 0.001) (Fig.

A decreasing trend for in-hospital mortality was seen from 18.1% in 2003 to 15.1% in 2010 (unadjusted OR [per year], 0.970; 95% CI, 0.967-0.973; P <.001) ( Figure 3A ).

Like structural parameters, all neuropsychological variables showed a decreasing trend with advancing stage ( p < 0.001).

These results were consistent with the findings from Western blotting.Similarly, IHC analysis demonstrated a significant increase in p62 expression from 1 week to 2 weeks of age ( p < 0.001), peaking at 2 weeks of age, and then exhibiting a decreasing trend from 2 weeks to 8 weeks of age ( p < 0.001) ( Figure 5 D).

BMI showed a decreasing trend with increasing RDW ( P < 0.001).

The amount of sebum showed a decreasing trend overall (within-group P < 0.001) and prominently for the flutamide group (β = −4.3; between-group P < 0.01).

Compared to the LD-dark, HR significantly decreased in LL3 and LL4 (both p < 0.001), with a decreasing trend (β = –14.345, p < 0.001, R 2 = 0.736).